Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Fineline Cube Dec 21, 2025
Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Fineline Cube Dec 20, 2025
Company Drug

MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study

Fineline Cube Jul 28, 2022

Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...

Company Deals

CSPC Jushi Biopharm’s SYSA1801 ADC Secures Licensing Deal with Elevation Oncology

Fineline Cube Jul 28, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary, CSPC Jushi Biopharmaceutical Co.,...

Policy / Regulatory

CDE Releases 61st Batch of Generic Reference Preparations, 34 New Specs Added

Fineline Cube Jul 28, 2022

The Center for Drug Evaluation (CDE) has released the 61st batch of chemical generic reference...

Company

Immunochina Pharmaceuticals Secures CAR-T Production License in Beijing

Fineline Cube Jul 28, 2022

Beijing-based Immunochina Pharmaceuticals has obtained a Drug Production License for its chimeric antigen receptor (CAR)...

Company Deals

Kolo Medical Raises RMB 100M in Series B2 to Launch High-Frequency Ultrasound Imaging System

Fineline Cube Jul 28, 2022

Suzhou-based Kolo Medical Inc., a leader in next-generation semiconductor ultrasound CMUT (Capacitive Micromachined Ultrasonic Transducer)...

Company Drug

Nestle Launches China’s First Cancer-Focused FSMP Product Oral Impact Su Yi Su

Fineline Cube Jul 28, 2022

Switzerland-based Nestle announced the launch of China’s first “foods for special medical purposes” (FSMP) product...

Company Digital

Sanofi’s Hornstein Sees China’s Online Hospitals Boosting Digital Health Strategy

Fineline Cube Jul 28, 2022

Sanofi’s outgoing China market president, Pius Hornstein, expressed confidence in the potential of China’s online...

Company Drug

Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)

Fineline Cube Jul 27, 2022

China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in...

Company Drug

Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review

Fineline Cube Jul 27, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...

Company Deals

CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment

Fineline Cube Jul 27, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG:...

Company Deals

Wanbangde Pharmaceutical to Acquire Consun Pharma Shares in RMB 2.2B Deal

Fineline Cube Jul 27, 2022

China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun...

Company Drug

Brii Biosciences’ COVID-19 Antibody Cocktail Effective Against Omicron BA.4/5 and BA.2.12.1

Fineline Cube Jul 27, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced that its anti-COVID-19 antibody cocktail amubarvimab + romlusevimab...

Company Deals

CMS Acquires Wuhan YZY Biopharma’s Bispecific Antibody Assets for Fundus Disease

Fineline Cube Jul 27, 2022

China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY...

Company Deals R&D

HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration

Fineline Cube Jul 27, 2022

China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging...

Company Deals

Roche Diagnostics and Topgen Biopharm Launch Innovation Center in Chongqing

Fineline Cube Jul 27, 2022

Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic...

Company Deals

Hybio Pharmaceutical Signs Tech Transfer Deal with China’s CDC for COVID-19 Vaccine Peptide Sequences

Fineline Cube Jul 27, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that it has signed a technology transfer...

Company Deals

Yunnan Baiyao and Huawei Partner on AI-Driven Drug Development

Fineline Cube Jul 27, 2022

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a...

Company Drug

Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer

Fineline Cube Jul 27, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...

Company Deals

Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal

Fineline Cube Jul 26, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme...

Company Drug

SinoPharm CNBG’s F61 Monoclonal Antibody Receives NMPA Clinical Trial Approval

Fineline Cube Jul 26, 2022

SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus...

Posts pagination

1 … 578 579 580 … 600

Recent updates

  • Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
  • BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
  • Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
  • TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.